Ezra Cohen, Chief Medical Officer of Oncology at Tempus Labs, shared on LinkedIn:
“Novel dual targeting mechanism demonstrating single-agent activity in normally anti-PD1 unresponsive tumors.
Hats off to the investigators for also selecting phase 2 dose based on biologic parameters rather than maximal tolerability or manufacturability.
Worth watching and ripe for combinatorial approaches.”
Title: Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial
Authors: Ryan J. Sullivan, Nicholas P. Tschernia, Claire F. Friedman, Mercedes Herrera, Guru P. Sonpavde, Kai He, Antoine Italiano, Aurélien Marabelle, Matthieu Roulleaux-Dugage, François-Xavier Danlos, Elena Garralda Cabanas, Alberto Hernando-Calvo, Manuel Pedregal, Aparna Parikh, Gopakumar Iyer, Ahmed Zakari, E. John Wherry, Jeffrey Schlom, Renee N. Donahue, Shannon McCue, Sharon Cross, Karunya Srinivasan, Lisa Benincosa, Madan Katragadda, Zhenming Shun, Kevin Chin, Zhen Su, Ke Liu, Lillian L. Siu, James L. Gulley.
Other articles about Ezra Cohen on OncoDaily.